Read on Twitter
Four pharmaceutical companies have announced the preliminary results of their COVID-19 vaccine: Pfizer, Moderna, AstraZeneca, Bharat Biotech.
What do you need to know?
Thread: https://science.thewire.in/health/covid-19-vaccines-immunisation-insufficient-tests-financial-stake-vaccine-related-injuries/
What do you need to know?
Thread: https://science.thewire.in/health/covid-19-vaccines-immunisation-insufficient-tests-financial-stake-vaccine-related-injuries/
1. Pfizer/BioNTech
They have said that their vaccine candidate was found to be “more than 90% effective in preventing COVID-19” among trial participants. https://science.thewire.in/the-sciences/pfizer-biontech-covid-19-vaccine-final-trial-results-95-success-rate/
They have said that their vaccine candidate was found to be “more than 90% effective in preventing COVID-19” among trial participants. https://science.thewire.in/the-sciences/pfizer-biontech-covid-19-vaccine-final-trial-results-95-success-rate/
Pfizer also said its vaccine candidate was well-tolerated and that the only severe adverse events trial participants reported were fatigue and headaches after the second dose. https://science.thewire.in/the-sciences/pfizer-biontech-covid-19-vaccine-final-trial-results-95-success-rate/
However, Pfizer/BioNTech’s candidate needs to be stored at ultra-cold temperatures, of -70º C, making it a logistical challenge to distribute in India. https://science.thewire.in/the-sciences/pfizer-biontech-covid-19-vaccine-final-trial-results-95-success-rate/
2. Moderna
They've said their experimental vaccine candidate was 94.5% effective in preventing COVID-19 based on interim data from a clinical trial in its late stage. https://science.thewire.in/the-sciences/moderna-covid-19-vaccine-94-5-effective/
They've said their experimental vaccine candidate was 94.5% effective in preventing COVID-19 based on interim data from a clinical trial in its late stage. https://science.thewire.in/the-sciences/moderna-covid-19-vaccine-94-5-effective/
Moderna’s vaccine can be stored for up to six months at -20º C though it is expected to be stable for 30 days at normal fridge temperatures, of 2-8º C. https://science.thewire.in/the-sciences/moderna-covid-19-vaccine-94-5-effective/
However, Moderna said a significant proportion of volunteers experienced severe aches and pains after taking the second dose.
For India, its price of $37.50/dose also makes it inaccessible. https://science.thewire.in/health/gagandeep-kang-interview-covid-19-public-health-surveillance-lockdown-vaccines-transcript/
For India, its price of $37.50/dose also makes it inaccessible. https://science.thewire.in/health/gagandeep-kang-interview-covid-19-public-health-surveillance-lockdown-vaccines-transcript/
3. Oxford-AstraZeneca
They've said that their vaccine candidate was 90% effective in preventing COVID-19 when administered as a half dose followed by a full dose at least one month apart. https://science.thewire.in/health/astrazeneca-says-its-covid-19-vaccine-candidate-is-70-efficacious/
They've said that their vaccine candidate was 90% effective in preventing COVID-19 when administered as a half dose followed by a full dose at least one month apart. https://science.thewire.in/health/astrazeneca-says-its-covid-19-vaccine-candidate-is-70-efficacious/
The AstraZeneca candidate, developed by Oxford University researchers, can be stored at minus 2-8º C – achievable by an ordinary refrigerator.
Gagandeep Kang has said that of the three, this candidate might be the most viable candidate for India. https://thewire.in/video/watch-pfizer-moderna-covid-19-oxford-vaccines-gagandeep-kang-karan-thapar
Gagandeep Kang has said that of the three, this candidate might be the most viable candidate for India. https://thewire.in/video/watch-pfizer-moderna-covid-19-oxford-vaccines-gagandeep-kang-karan-thapar
4. Bharat Biotech: Covaxin
Bharat Biotech, the maker of India's homegrown vaccine candidate, said its COVID-19 vaccine is expected to be 60% efficacious. https://science.thewire.in/health/covid-19-bharat-biotechs-covaxin-expected-to-be-60-effective-company-says/
Bharat Biotech, the maker of India's homegrown vaccine candidate, said its COVID-19 vaccine is expected to be 60% efficacious. https://science.thewire.in/health/covid-19-bharat-biotechs-covaxin-expected-to-be-60-effective-company-says/
But Bharat Biotech has not released data from the vaccine candidate’s phase 1 and 2 trials.
Details of its phase 3 trial are also unclear. https://science.thewire.in/health/covid-19-vaccines-immunisation-insufficient-tests-financial-stake-vaccine-related-injuries/
Details of its phase 3 trial are also unclear. https://science.thewire.in/health/covid-19-vaccines-immunisation-insufficient-tests-financial-stake-vaccine-related-injuries/
The company also stated one participant had developed an adverse reaction to the candidate in phase 1 trials, which it reported to the Central Drugs Standard Control Organisation. https://science.thewire.in/health/covid-19-bharat-biotechs-covaxin-expected-to-be-60-effective-company-says/
